These targeted treatments can improve survival in patients with HER2-positive invasive breast cancer.
Advanced Search Abstract Immunohistochemical assays for estrogen receptors ERs and progesterone receptors PRs have not been surveyed for technical validity.
In the present study, the reliability of the immunohistochemical assay for ER and PR was evaluated using data from laboratories participating in external quality assessment EQA during a 2-year period. Technical variables associated with reliable immunostaining were analyzed.
The efficiency of the antigen retrieval step was identified as the single most important contributory factor influencing the overall reproducibility of the assays.
Inadequate assay sensitivity, with subsequent weak staining, was the main cause of poor and variable results by laboratories using microwave antigen retrieval; too short a heating time was identified as the principal contributory factor.
Extension of the heating time resulted in significant improvement regardless of all other variables in the immunohistochemical protocol.
Continual participation in EQA is an effective means for identifying and ameliorating variables that influence the reliability of immunohistochemical assays for predictive markers, thereby assisting in technical validation and standardization.When progesterone receptors are present on cell walls, endocrine (hormone) therapy can be used as a treatment, along with removal of ovaries and/or adrenal glands.
People who are PR positive have a better prognosis than those with PR negative breast cancer, and the prognosis is even better if estrogen receptors are also present. Progesterone Receptor B (PR-B) is a kDa member of the NR3 subfamily within the nuclear hormone receptor family of proteins.
It is expressed in female reproductive tissues as well as neurons throughout the CNS. Abstract. Response to endocrine therapy in breast cancer correlates with estrogen receptor (ER) and progesterone receptor (PR) status.
It was originally hypothesized that the ability of PR to predict response to endocrine therapy was due to the fact that PR is an estrogen-regulated gene and that its levels represented a marker of functional ER activity.
Understanding Estrogen, Progesterone, Her2/neu and Ki67 estrogen and progesterone is determined using a test called the hormone receptor assay. The result of the hormone receptor assay test is important to help you and your physician plan the medications for your treatment.
Estrogen receptor (ER) status is a strong predictor of response to hormonal therapy in women with breast cancer. Not only presence of ER, but also level of expression has been shown to correlate with time to recurrence in patients undergoing therapy with tamoxifen or anastrozole.
Estrogen and progesterone receptors are found in breast cancer cells that depend on estrogen and related hormones to grow.
All patients with invasive breast cancer or a breast cancer recurrence should have their tumors tested for estrogen and progesterone receptors.